0001193125-18-128747.txt : 20180524 0001193125-18-128747.hdr.sgml : 20180524 20180424160203 ACCESSION NUMBER: 0001193125-18-128747 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20180424 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PROTEOSTASIS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001445283 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 80 GUEST STREET STREET 2: 5TH FLOOR CITY: BOSTON STATE: MA ZIP: 02135 BUSINESS PHONE: 617-225-0096 MAIL ADDRESS: STREET 1: 80 GUEST STREET STREET 2: 5TH FLOOR CITY: BOSTON STATE: MA ZIP: 02135 FORMER COMPANY: FORMER CONFORMED NAME: PROTEOSTASIS THERAPEUTICS INC DATE OF NAME CHANGE: 20080916 CORRESP 1 filename1.htm CORRESP

VIA EDGAR

April 24, 2018

 

  Re: Proteostasis Therapeutics, Inc.

Registration Statement on Form S-3

(File No. 333-224180)

SECURITIES AND EXCHANGE COMMISSION

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Proteostasis Therapeutics, Inc. hereby requests that the effective date of the above-referenced Registration Statement be accelerated so that it may become effective at 4:00 p.m., Washington, D.C. time, on April 26, 2018, or as soon as possible thereafter.

Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Goodwin Procter LLP, by calling Sarah Ashfaq, Esq., at (212) 459-7238.

 

Very truly yours,
PROTEOSTASIS THERAPEUTICS, INC.

By:

  

/s/ Meenu Chhabra

  Name:   Meenu Chhabra
  Title:   Chief Executive Officer

 

cc: Jeff Held, Proteostasis Therapeutics, Inc.

Mitchell S. Bloom, Goodwin Procter LLP

John Mutkoski, Goodwin Procter LLP